With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

About The Study: Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in ...

For example, GLP-1 agonist users had significantly higher rates of obesity compared with the general type 1 population (69.4% vs 26.8%), while SGLT2 inhibitor users had higher proportions of ...

In any case, the present analysis was still limited by the lack of accounting for variables such as the different types and doses of GLP-1 agonists used, the difference between a surgery versus ...

Of those, 4,052 were prescribed a GLP-1 receptor agonist. Compared with controls, those prescribed medication were slightly older (mean 15.5 years vs 14.7 years), more often female, had higher body ...